Arrowhead Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2836 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity - Nov 4th, 2026 5:30 am
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results - Nov 3rd, 2026 2:00 pm
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 - Nov 2nd, 2026 5:30 am
3 Biotech Stocks With Upside Of Up To 80% - Oct 30th, 2026 10:21 pm
Arrowhead gains UK marketing authorisation for Redemplo - Oct 28th, 2026 4:50 am
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides - Oct 27th, 2026 9:36 am
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own - Oct 23rd, 2026 8:09 pm
Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap? - Oct 16th, 2026 3:09 am
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases - Oct 15th, 2026 9:08 am
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study - Oct 14th, 2026 5:02 pm
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial - Oct 14th, 2026 11:21 am
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Oct 14th, 2026 10:43 am
Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know - Oct 14th, 2026 9:36 am
Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier - Oct 14th, 2026 6:37 am
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers - Oct 14th, 2026 5:30 am
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist - Oct 11th, 2026 8:17 pm
3 Biotech Stocks To Watch In October 2026 - Oct 9th, 2026 6:16 pm
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - Oct 7th, 2026 5:30 am
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Sep 29th, 2026 5:30 am